The Scientist

» drug development

Most Recent

image: Neurologist Reveals Insider Information

Neurologist Reveals Insider Information

By | November 26, 2012

A Michigan University clinical researcher allegedly supplied a fund manager with information about drug trial results that the fund used to rake in more than $270 million.

1 Comment

image: Gene Therapy Arrives in Europe

Gene Therapy Arrives in Europe

By | November 6, 2012

The European Commission approves the Western hemisphere’s first gene therapy, aimed at correcting a lipid-processing disorder.

7 Comments

image: Tumor Snipers

Tumor Snipers

By | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: Metabolomics Sheds Light on TB Drug

Metabolomics Sheds Light on TB Drug

By | November 1, 2012

Understanding the mechanism of a classic tuberculosis treatment could refine future strategies for TB drug development.

1 Comment

image: Beating Drug-Resistant TB

Beating Drug-Resistant TB

By | September 19, 2012

Reinvestigating a natural antibiotic compound reveals its potential as a tuberculosis drug.

1 Comment

image: Double-Edged TB Drug

Double-Edged TB Drug

By | September 12, 2012

A cheap pain reliever that can kill drug-resistant, tuberculosis-causing bacteria may never be tested.

2 Comments

image: Fears over Fast-Tracking Drugs

Fears over Fast-Tracking Drugs

By | September 10, 2012

Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.

0 Comments

image: Rethinking Herbal Medicine

Rethinking Herbal Medicine

By | September 10, 2012

A phylogenetic study of traditional plant remedies could aid drug development.

21 Comments

image: Clinical Trial Misfortune

Clinical Trial Misfortune

By | August 28, 2012

A human trial of a hepatitis C treatment is shut down after one of the participants died.

1 Comment

image: Orphan Drugs Lucrative

Orphan Drugs Lucrative

By | August 24, 2012

The market for drugs that target rare diseases is expected to rival big pharma blockbusters in the coming decades.

1 Comment

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech